Interleukin-12 gene adjuvant increases the immunogenicity of virus-like particles of human papillomavirus type 16 regional variant strain

Abstract

VLP of HPV16 variant strain isolated in East China could induce humoral immunity and cellular immunity in mice, and IL-12 recombinant plasmid can enhance cellular immunity.

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

“…HPV L1 VLPs for types 16 and 18 expressed in E. coli (eVLP) were supplied by Xiamen Innovax. 26,27 Each well of microtiter plate was coated with 0.27 μg HPV-16 bVLPs, 0.27 μg HPV-18 bVLPs, 0.5 μg HPV-16 eVLPs, or 0.4 μg HPV-18 eVLP resuspended in phosphate buffer at 4 °C overnight, and then the plates were blocked with blocking solution. After washing, diluted serum samples, diluted reference serum samples and controls were added and incubated for 45 min at 37 °C.…”

Immune response assessment of inactivated Newcastle disease virus liposomal-based vaccine

“…26 In humans, cytokines such as IFN-, IL-8, and IL-23 levels in serum have been labeled as immunomolecules and used for determining Th-1 and Th-17 responses against Mycobacterium avium complex diseases, tuberculosis, and papillomavirus infections. [26][27][28] The current work is the first to employ a ChIFN-g measurement, directly in the serum, as a monitoring tool to assess the CMI response in poultry post vaccination. However, the background serum ChIFN-g levels also need to be estimated in chickens exposed to different stressful conditions in the field and in differing bird ages and breeds.…”

Safety of anEscherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine

“…These antigens have been shown to elicit high titers of specific neutralizing antibody that can effectively neutralize infection of pseudovirus. 14,15 Based on these VLPs, a bivalent (types 16 and 18) HPV vaccine candidate was developed and shown to be safe and highly immunogenic in preclinical studies (unpublished data). This vaccine was approved for human trials by the China Food and Drug Administration (CFDA).…”

“…14,15 The production of this vaccine has been described previously. 14,15 In brief, recombinant plasmids containing the HPV 16 or 18 L1 genes were transferred into E. coli. The bacteria were centrifuged and lysed, and the proteins were purified by sequential chromatography.…”